Severe Asthma Clinical Trial
Official title:
Klinisches Register Schweres Asthma
The German Asthma Net e.V. focusses on science and research in patients with severe asthma. This includes, in particular, the optimization of medical care and treatment for patients with severe asthma as well as the elucidation and information. An unavoidable basis for a better understanding of severe asthma is the registration and comprehensive characterization of a large patient population. To date, there are only few reliable data on incidence, prevalence, phenotypes and treatment of patients with severe asthma. For this reason, the German Asthma Net e.V. was established in December 2011 as a clinical registry for patients with severe asthma, initially set up on a national basis.
Status | Recruiting |
Enrollment | 4500 |
Est. completion date | November 1, 2026 |
Est. primary completion date | November 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years and older |
Eligibility | Definition: Severe asthma in children and adolescents Poor symptom control in the last year despite (medium to) high doses of anti-inflammatory maintenance treatment: (i) Age 6-18 years (at inclusion) (ii) Asthma diagnosis made by a medical doctor (iii) Potential differential diagnoses excluded (iv) Good compliance and trained inhalation technique (v) Evidence of: a. Positive bronchodilator reversibility testing (= 12% increase in FEV1 after SABA) or b. Significant bronchial hyperreactivity (BHR) after unspecific provocation test (e.g. methacholine challenge or treadmill) according to ATS criteria (Am J Respir Crit Care Med 2000) (vi) High level of treatment: 1. Maintenance treatment with high doses of ICS (>400 µg budesonide or equivalent / = 200 µg of fluticasone as monotherapy) or 2. Maintenance treatment with medium to high doses of ICS (=400 µg budesonide or equivalent / = 200 µg fluticasone) combined with LABA and/or LTRA and/or theophylline or 3. Treatment with oral steroids for = 3 months (vii) Poor asthma control: a. Inadequate symptom in the past 4 weeks: i. asthma symptoms =3 x / week or use of rescue medication =3 x / week; or ii. activity limitations due to asthma; or iii. any nighttime asthma symptoms; or b. = 1 exacerbation in the last year with = 3 days of OCS treatment or hospitalisation or b. Poor lung function with reduced Tiffeneau index or FEV1 at inclusion (viii) written informed consent (parent or legal guardian) Exclusion criteria: (i) Diagnosis of other obstructive or systemic pulmonary diseases (e.g. cystic fibrosis, COPD) despite BPD at inclusion (ii) Other congenital lung diseases or pulmonary malformations (iii) Other significant chronic diseases (iv) Congenital or acquired heart defects with significant functional limitations Definition: Severe asthma in adults High level of treatment (A), i.e. step 5 of GINA guideline or (B) medium level of treatment and poor symptom control: (A) High level of treatment: 1. Maintenance treatment with high-dose inhaled corticosteroids (= 1000 µg beclomethasone (BDP, powder) or equivalent) in combination with LABA or LTRA or theophylline or 2. Maintenance treatment with oral corticosteroids (OCS) for =3 months independent of other asthma treatments or 3. Treatment with monoclonal antibodies independent of other asthma treatments B) Medium level of treatment and poor symptom control: 1. Maintenance treatment with medium to high doses of ICS (= 500 µg BDP (powder) or equivalent) in combination with LABA or LTRA or theophylline and 2. Poor symptom control: (i) asthma symptoms = 3 x / week or use of rescue medication = 3 x / week; or (ii) activities limited due to asthma; or (iii) any nighttime asthma symptoms; or (iv) = 1 exacerbation in the last year with = 3 days of OCS treatment or (v) FEV1<80% of predicted |
Country | Name | City | State |
---|---|---|---|
Germany | Kardiologische und fachinternistische ÜBAG Dr. Sandrock und Partner | Altdorf | |
Germany | Universitätsklinikum Augsburg Kinderpulmologie und -allergologie | Augsburg | |
Germany | Praxis Dr. Grün | Bad Windsheim | |
Germany | CIMS Studienzentrum Bamberg | Bamberg | |
Germany | Lungenpraxis Tegel | Berlin | |
Germany | Evangelisches Klinikum Bethel v. Bodelschwinghsche Stiftungen Bethel | Bielefeld | |
Germany | Lungenpraxis Medicum Böblingen | Böblingen | |
Germany | Helios Lungen- und Allergiezentrum Bonn | Bonn | |
Germany | Universitätsnedizin Bonn | Bonn | |
Germany | Zentrum für Kinderheilkunde, Klinik und Poliklinik für Allgemeine Pädiatrie, Allergieabteilung | Bonn | |
Germany | Prof.-Hess-Kinderklinik Bremen-Mitte | Bremen | |
Germany | MECS Cottbus | Cottbus | |
Germany | Evangelisches Krankenhaus Düsseldorf | Düsseldorf | |
Germany | Lunge im Zentrum | Erlangen | |
Germany | Universitätsmedizin Essen | Essen | |
Germany | Pneumologie am Schelztor Esslingen | Esslingen | |
Germany | Praxis Dr. Herden | Freising | |
Germany | ALB FILS Kliniken | Göppingen | |
Germany | Hamburger Institut für Therapieforschung GmbH | Hamburg | |
Germany | Medizinische Hochschule Hannover | Hanover | |
Germany | Praxisgmeinschaft Dr. Abenhardt und Jochen Hinrichs-Pavlik | Heidelberg | |
Germany | Thoraxklinik Heidelberg gGmbH | Heidelberg | |
Germany | Lungenarztpraxis Dr. Hubatsch | Heilbronn | |
Germany | Atemwegszentrum Kaiserslautern | Kaiserslautern | |
Germany | MVZ Klinikum Kempten | Kempten | |
Germany | Pneumologische Gemeinschaftspraxis | Koblenz | |
Germany | Lungenpraxis Konstanz | Konstanz | |
Germany | DONAUISAR Klinikum Deggendorf-Dingolfing-Landau | Landau an der Isar | |
Germany | Asthma Allergiezentrum | Leverkusen | |
Germany | Lungenfachklinik Medizinische Klinik I, Pneumologie | Löwenstein | |
Germany | IKF Pneumologie GmbH & Co. KG | Mainz | |
Germany | Lungenfacharztpraxis Dr. C. Lüttecke-Hecht | Mainz | |
Germany | Lungenfacharztpraxis Dr. Gall | Mainz | |
Germany | Univsersitätsmedizin Mainz | Mainz | |
Germany | Dr. von Haunersches Kinderspital | München | |
Germany | LMU Klinikum der Universität München, Ambulanz für Schweres Asthma (Erwachsene) | München | |
Germany | Universitätsklinikum Regensburg | Regensburg | |
Germany | Universitätsmedizin Rostock, Med. Klinik I, Abt. Pneumologie & Interdiszipl. Internistische Intensivmedizin | Rostock | |
Germany | Lungenpraxis Schleswig/ Respiratio | Schleswig | |
Germany | Ambulante Pneumologie mit Allergiezentrum (BAG) | Stuttgart | |
Germany | RBK Lungenzentrum Stuttgart | Stuttgart | |
Germany | Internistische Gemeinschaftspraxis Bitburg-Trier | Trier | |
Germany | Uniklinik Ulm, Sektion Pneumologie, Klinik für Innere Medizin II | Ulm | |
Germany | Fachkliniken Wangen | Wangen Im Allgäu | |
Germany | Marien-Hospital, Klinik für Kinder- und Jugendmedizin | Wesel |
Lead Sponsor | Collaborator |
---|---|
German Asthma Net e.V. | AstraZeneca, Chiesi Farmaceutici S.p.A., GlaxoSmithKline, Sanofi |
Germany,
Bal C, Idzko M, Skrgat S, Koch A, Milger K, Schulz C, Zehetmayer S, Hamelmann E, Buhl R, Korn S; collaborators from the German Asthma Net (GAN). Fraction of exhaled nitric oxide is associated with disease burden in the German Asthma Net severe asthma coho — View Citation
Bal C, Pohl W, Milger K, Skowasch D, Schulz C, Gappa M, Koerner-Rettberg C, Jandl M, Schmidt O, Zehetmayer S, Taube C, Hamelmann E, Buhl R, Korn S, Idzko M; German Asthma Net (GAN) study group. Characterization of Obesity in Severe Asthma in the German As — View Citation
Korn S, Milger K, Skowasch D, Schulz C, Mohrlang C, Wernitz M, Paulsson T, Hennig M, Buhl R. Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study). J Asthma Allergy. 2023 May 11;16:541-552 — View Citation
Milger K, Skowasch D, Hamelmann E, Mummler C, Idzko M, Gappa M, Jandl M, Korner-Rettberg C, Ehmann R, Schmidt O, Taube C, Holtdirk A, Timmermann H, Buhl R, Korn S. Bronchodilator reversibility in the GAN severe asthma cohort. J Investig Allergol Clin Immu — View Citation
Milger K, Suhling H, Skowasch D, Holtdirk A, Kneidinger N, Behr J, Timmermann H, Schulz C, Schmidt O, Ehmann R, Hamelmann E, Idzko M, Taube C, Lommatzsch M, Buhl R, Korn S. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Symptom Control | Changes in symptom control at baseline and during the follow-up period and at study end using the Asthma Control Test (ACT). | Baseline, four months, yearly for up to 15 years | |
Secondary | Exacerbations | Number of exacerbation with/without hospitalization | Baseline, four months, yearly for up to 15 years | |
Secondary | Utilization of the health care system | Number of visits at a pneumologist/ specialist, number of emergency consultations, number of hospitalizations, number of rehabilitation stays | Baseline, yearly for up to 15 years | |
Secondary | Symptoms and health-related quality of life | Asthma Control Test (ACT: 5 questions, scale 1- 5, min score 5, max score 25, the lower the score the better the Asthma control) | Baseline, yearly for up to 15 years | |
Secondary | Quality of Life Questionnaire | Mini Asthma Quality of Life Questionnaire (Mini-AQLQ: 15 questions, scale 1 to 7, min score 15, max score 105, the higher the score, the better the quality of life) | Baseline, yearly for up to 15 years | |
Secondary | Asthma Control Questionnaire | Asthma Control Questionnaire ACQ: 5 questions, scale 0 to 6, min score 0, max score 30, the lower the score the better the Asthma control) | Baseline, yearly for up to 15 years | |
Secondary | Forced Exhaled Volume in 1 second (FEV1) | FEV1 at consultation, FEV1 last 2 years, changes in FEV1 in liter from the target value | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Forced Vital Capacity (FVC) | FVC at consultation, FEV1 last 2 years, changes in FEV1 in liter from the target value | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Changes in medication | changes in substances if there is a new drug used. | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Changes in dose in mg | Changes in dose in mg | 4 months, yearly for up to 15 years | |
Secondary | Fraction of exhaled nitric oxide (FeNo) | Changes in FeNo in ppb | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Blood Gas analysis | pO2 in kPa/ mmHg, pCO2 in kPa/ mmHg | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Blood Gas analysis | Blood-oxygen saturation in % | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Leucocytes | Changes in leucocytes in nl | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Neutrophilic granulocytes | Changes in Neutrophilic granulocytes in nl or % | Baseline, 4 months, yearly for up to 15 years | |
Secondary | Eosinophilic granulocytes | Changes in Eosinophilic granulocytes in µl or % | Baseline, 4 months, yearly for up to 15 years | |
Secondary | CO diffusion capacity | Changes in mmol/min/kPa/ % | Baseline, yearly for up to 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05018299 -
Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
|
Phase 2 | |
Recruiting |
NCT05472324 -
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
|
Phase 2 | |
Recruiting |
NCT04914078 -
Severe Asthma Exacerbations and Mepolizumab Treatment
|
||
Completed |
NCT05576454 -
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
|
Phase 1 | |
Recruiting |
NCT04520165 -
Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
|
||
Recruiting |
NCT04438408 -
National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
|
||
Not yet recruiting |
NCT04463836 -
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
|
||
Enrolling by invitation |
NCT06421402 -
K-HEALTH in AIR - Barcelona Pilot - Cohort
|
||
Recruiting |
NCT03377920 -
Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.
|
N/A | |
Recruiting |
NCT04565483 -
Predictive Signature of Benralizumab Response
|
Phase 4 | |
Recruiting |
NCT04045587 -
International Severe Asthma Registry: Canadian Cohort
|
||
Completed |
NCT05616338 -
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
|
N/A | |
Active, not recruiting |
NCT02038374 -
Clinico-biological Correlation of Severe Asthma in Children
|
N/A | |
Active, not recruiting |
NCT02114034 -
Cohort Analysis of Clinical and Biological Severe Childhood Asthma
|
||
Not yet recruiting |
NCT03532685 -
Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up
|
N/A | |
Completed |
NCT03931954 -
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
|
||
Recruiting |
NCT03984253 -
Swiss Severe Asthma Register
|
||
Recruiting |
NCT03435237 -
Phenotyping Asthma for Bronchial Thermoplasty
|
||
Recruiting |
NCT03476109 -
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
|
Phase 4 | |
Active, not recruiting |
NCT06389058 -
Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System
|